ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This is a multicentre, randomised (2:1), double blind, non-comparative phase II trial of
ZD1839 and placebo in combination with chemotherapy in patients with metastatic breast
cancer.